Why Aptose Biosciences Stock Is Skyrocketing Today
The huge gain came after the company provided a fourth-quarter update following the market close on Tuesday that featured new results from an early-stage clinical study evaluating luxeptinib in treating acute myeloid leukemia (AML). Aptose announced "encouraging anti-leukemic activity" has been observed so far in its phase 1 study of luxeptinib in treating AML. One patient in the study has experienced a complete remission with no safety issues.